Abstract
We conducted a multi-center, retrospective study to evaluate the clinical effect of chemoradiotherapy (CRT) with paclitaxel (PTX) in patients with angiosarcoma. We compared 12 patients treated with PTX and 18 patients treated with docetaxel (DTX). The results showed identical response ratios for CRT with PTX and CRT with DTX. Among the patients treated with PTX, the response ratio decreased significantly when the radiation dose was less than 70 Gy. Serious adverse effects were less common in patients treated with PTX than in those treated with DTX. All the serious adverse events occurred in patients who received PTX doses equal to or over 70 mg/m2. In conclusion, when we reduced the PTX dose and completed target radiation dose, CRT with PTX achieved a response ratio identical to that of CRT with DTX, but with less toxicity.
